CNS or classic drugs for the treatment of pain in functional dyspepsia? A systematic review and meta-analysis of the literature

Pain Physician

Volumn 11, Issue 5, 2008, Pages 597-609

  Passos, Maria do Carmo Friche ^a,b,c   Duro, Debora ^a   Fregni, Felipe ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c NONE   (United States)

Author keywords

Antianxiety; Antidepressants; Antisecretory agents; Brain activity; Epigastric pain; Functional dyspepsia; Prokinetics

Indexed keywords

12 SULFODEHYDROABIETIC ACID; ALEMCINAL; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CENTRAL NERVOUS SYSTEM AGENTS; CIMETIDINE; CISAPRIDE; FAMOTIDINE; FLUOXETINE; ITOPRIDE; LANSOPRAZOLE; MOSAPRIDE CITRATE; OMEPRAZOLE; PLACEBO; PROKINETIC AGENT; REBAMIPIDE; SIMETHICONE; STOMACH SECRETION INHIBITOR; SULPIRIDE; TANDOSPIRONE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANALGESIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSPEPSIA; EPIGASTRIC FULLNESS; HUMAN; MEDLINE; META ANALYSIS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SATIETY; SYMPTOMATOLOGY; SYSTEMATIC REVIEW;

EID: 57649181420     PISSN: 15333159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Talley NJ. Non-ulcer dyspepsia: myths and realities. Aliment Pharmacol Ther 1991; 5 Suppl 1:145-162.
2. Talley NJ. Spectrum of chronic dyspepsia in the presence of the irritable bowel syndrome. Scand J Gastroenterol Suppl 1991; 182:7-10.
3. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 Suppl 2:II37-42.
4. Shaib Y, El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. Am J Gastroenterol 2004; 99:2210-2216.
5. Tougas G, Chen Y, Hwang P, Liu MM, Eggleston A. Prevalence and impact of upper gastrointestinal symptoms in the Canadian population: Findings from the DIGEST study. Domestic/International Gastroenterology Surveillance Study. Am J Gastroenterol 1999; 94:2845-2854.
6. Agreus L, Svardsudd K, Nyren O, Tibblin G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 1995; 109:671-680.
7. Talley NJ, Locke GR, 3rd, Lahr BD, Zinsmeister AR, Tougas G, Ligozio G, Rojavin MA, Tack J. Functional dyspepsia, delayed gastric emptying, and impaired quality of life. Gut 2006; 55:933-939.
8. Colin-Jones D, Bloom B, Bodemar G, Crean G, Freston J, Malagelada J, Nyren O, Petersen H, Piper D. Management of dyspepsia: report of a working party. Lancet 1988; 1:576-579.
9. Tack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130:1466-1479.
10. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity: Facts, speculations, and challenges. Gut 2001; 48:125-131.
11. Flier SN, Rose S. Is functional dyspepsia of particular concern in women? A review of gender differences in epidemiology, pathophysiologic mechanisms, clinical presentation, and management. Am J Gastroenterol 2006; 101:S644-653.
12. Tack J, Lee KJ. Pathophysiology and treatment of functional dyspepsia. J Clin Gastroenterol 2005; 39:S211-216.
13. Rees WD, Miller LJ, Malagelada JR. Dyspepsia, antral motor dysfunction, and gastric stasis of solids. Gastroenterology 1980; 78:360-365.
14. Perri F, Clemente R, Festa V, Annese V, Quitadamo M, Rutgeerts P, Andriulli A. Patterns of symptoms in functional dyspepsia: Role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998; 93:2082-2088.
15. Silverman DH, Munakata JA, Ennes H, Mandelkern MA, Hoh CK, Mayer EA. Regional cerebral activity in normal and pathological perception of visceral pain. Gastroenterology 1997; 112:64-72.
16. Stephan E, Pardo JV, Faris PL, Hartman BK, Kim SW, Ivanov EH, Daughters RS, Costello PA, Goodale RL. Functional neuroimaging of gastric distention. J Gastrointest Surg 2003; 7:740-749.
17. Vandenberghe J, Dupont P, Van Oudenhove L, et al. Regional cerebral blood flow during gastric balloon distention in functional dyspepsia. Gastroenterology 2007; 132:1684-1693.
18. Fisher RS, Parkman HP. Management of nonulcer dyspepsia. N Engl J Med 1998; 339:1376-1381.
19. Moayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006: CD001960.
20. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31:318-325.
21. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108:65-72.
22. Mine K, Kanazawa F, Hosoi M, Kinukawa N, Kubo C. Treating nonulcer dyspepsia considering both functional disorders of the digestive system and psychiatric conditions. Dig Dis Sci 1998; 43:1241-1247.
23. Talley NJ, Silverstein MD, Agreus L, Nyren O, Sonnenberg A, Holtmann G. AGA technical review: Evaluation of dyspepsia. American Gastroenterological Association. Gastroenterology 1998; 114:582-595.
24. Mansi C, Borro P, Giacomini M, Biagini R, Mele MR, Pandolfo N, Savarino V. Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. Aliment Pharmacol Ther 2000; 14:561-569.
25. Mearin F, Rodrigo L, Perez-Mota A, Balboa A, Jiménez I, Sebastián JJ, Patón C. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: A randomized, double-masked trial. Clin Gastroenterol Hepatol 2004; 2:301-308.
26. Amarapurkar DN, Rane P. Randomised, double-blind, comparative study to evaluate the efficacy and safety of ganaton (itopride hydrochloride) and mosapride citrate in the management of functional dyspepsia. J Indian Med Assoc 2004; 102:735-737, 760.
27. Holtmann G, Gschossmann J, Mayr P, Talley NJ. A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. Aliment Pharmacol Ther 2002; 16:1641-1648.
28. Gerson LB, Triadafilopoulos G. A prospective study of oesophageal 24-h ambulatory pH monitoring in patients with functional dyspepsia. Dig Liver Dis 2005; 37:87-91.
29. Lee JH, Kim JJ, Hahm KB, Lee DH, Kim N, Kim SK, Park JJ, Choi SR, Lee JH, Lee ST, Lee EH, Rhee JC. Efficacy and safety of ecabet sodium on functional dyspepsia: A prospective, double-blinded, randomized, multi-center controlled trial. World J Gastroenterol 2006; 12:2756-2761.
30. Seno H, Nakase H, Chiba T. Usefulness of famotidine in functional dyspepsia patient treatment: Comparison among prokinetic, acid suppression and antianxiety therapies. Aliment Pharmacol Ther 2005; 21 Suppl 2:32-36.
31. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315:629-634.
32. Mertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93:160-165.
33. Song CW, Chun HJ, Kim CD, Ryu HS, Choe JG, Hyun JH. Effects of levosulpiride in patients with functional dyspepsia accompanied by delayed gastric emptying. Korean J Intern Med 1998; 13:15-21.
34. Wu CY, Chou LT, Chen HP, Chang CS, Wong PG, Chen GH. Effect of fluoxetine on symptoms and gastric dysrhythmia in patients with functional dyspepsia. Hepatogastroenterology 2003; 50:278-283.
35. Distrutti E, Fiorucci S, Hauer SK, Pensi MO, Vanasia M, Morelli A. Effect of acute and chronic levosulpiride administration on gastric tone and perception in functional dyspepsia. Aliment Pharmacol Ther 2002; 16:613-622.
36. Champion MC, MacCannell KL, Thomson AB, Tanton R, Eberhard S, Sullivan SN, Archambault A. A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. Can J Gastroenterol 1997; 11:127-134.
37. Veldhuyzen van Zanten SJ, Cleary C, Talley NJ, Peterson TC, Nyren O, Bradley LA, Verlinden M, Tytgat GNJ. Drug treatment of functional dyspepsia: A systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91:660-673.
38. Vandenberghe J, Vos R, Persoons P, Demyttenaere K, Janssens J, Tack J. Dyspeptic patients with visceral hypersensitivity: Sensitisation of pain specific or multimodal pathways? Gut 2005; 54:914-919.
39. Camilleri M. Functional dyspepsia: Mechanisms of symptom generation and appropriate management of patients. Gastroenterol Clin North Am 2007; 36:649-664.
40. Patrizi F, Freedman SD, Pascual-Leone A, Fregni F. Novel therapeutic approaches to the treatment of chronic abdominal visceral pain. Scientific World Journal 2006; 6:472-490.
41. Mayer EA, Tillisch K, Bradesi S. Review article: Modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006; 24:919-933.
42. Hunt RH. Evolving concepts in the pathophysiology of functional gastrointestinal disorder. J Clin Gastroenterol 2002; 35:S2-6.
43. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology 2006; 130:1421-1434.
44. Kindt S, Tack J. Mechanisms of serotonergic agents for treatment of gastrointestinal motility and functional bowel disorders. Neurogastroenterol Motil 2007; 19 Suppl 2:32-39.
45. Ladabaum U, Roberts TP, McGonigle DJ. Gastric fundic distension activates fronto-limbic structures but not primary somatosensory cortex: a functional magnetic resonance imaging study. Neuroimage 2007; 34:724-732.
46. Drossman DA, Creed FH, Olden KW, Svedlund J, Toner BB, Whitehead WE. Psychosocial aspects of the functional gastrointestinal disorders. Gut 1999; 45 Suppl 2:1125-1130.
47. Talley NJ. Quality of life in functional dyspepsia. Scand J Gastroenterol Suppl 1996; 221:21-22.
48. Olden KW. Are psychosocial factors of aetiological importance in functional dyspepsia? Baillieres Clin Gastroenterol 1998; 12:557-571.
49. Drossman DA. Psychosocial factors and the disorders of GI function: What is the link? Am J Gastroenterol 2004; 99:358-360.
50. Hojo M, Miwa H, Yokoyama T, Ohkusa T, Nagahara A, Kawabe M, Asaoka D, Izumi Y, Sato N. Treatment of functional dyspepsia with antianxiety or antidepressant agents: Systematic review. J Gastroenterol 2005; 40:1036-1042.
51. Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia. A meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989; 11:169-177.
52. Finney JS, Kinnersley N, Hughes M, O'Bryan-Tear CG, Lothian J. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26:312-320.
53. Allescher HD, Bockenhoff A, Knapp G, Wienbeck M, Hartung J. Treatment of non-ulcer dyspepsia: A meta-analysis of placebo-controlled prospective studies. Scand J Gastroenterol 2001; 36:934-941.
54. Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: A meta-analysis. Am J Gastroenterol 2001; 96:689-696.
55. Abraham NS, Moayyedi P, Daniels B, Veldhuyzen Van Zanten SJ. Systematic review: The methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004; 19:631-641.
56. Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, Tanaka S, Nishi N, Chayama K, Haruma K. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007; 22:304-310.
57. Moayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. Gastroenterology 2004; 127:1329-1337.
58. Peura DA, Gudmundson J, Siepman N, Pilmer BL, Freston J. Proton pump inhibitors: Effective first-line treatment for management of dyspepsia. Dig Dis Sci 2007; 52:983-987.
59. Talley NJ, Meineche-Schmidt V, Pare P, Duckworth M, Räisänen P, Pap A, Kordecki H, Schmid V. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12:1055-1065.
60. Blum AL, Arnold R, Stolte M, Fischer M, Koelz HR. Short course acid suppressive treatment for patients with functional dyspepsia: Results depend on Helicobacter pylori status. The Frosch Study Group. Gut 2000; 47:473-480.
61. Wang WH, Huang JQ, Zheng GF, Xia HH, Wong WM, Liu XG, Karlberg J, Wong BC. Effects of proton-pump inhibitors on functional dyspepsia: A meta-analysis of randomized placebo-controlled trials. Clin Gastroenterol Hepatol 2007; 5:178-185; quiz 140.
62. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354:832-840.
63. Yeoh KG, Kang JY, Tay HH, Gwee KA, Tan CC, Teh M, Choo HF, Chintana-Wilde W. Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: A double-blind placebo-controlled trial. J Gastroenterol Hepatol 1997; 12:13-18.
64. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB, Mathias JR, Fumagalli I, Staessen D, Mack RJ. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14:1653-1661.
65. Miwa H, Osada T, Nagahara A, Ohkusa T, Hojo M, Tomita T, Hori K, Matsumoto T, Sato N. Effect of a gastro-protective agent, rebamipide, on symptom improvement in patients with functional dyspepsia: a double-blind placebo-controlled study in Japan. J Gastroenterol Hepatol 2006; 21:1826-1831.
66. Kato M, Watanabe M, Konishi S, Kudo M, Konno J, Meguro T, Kitamori S, Nakagawa S, Shimiz Y, Takeda H, Askaka M. Randomized, double-blind, placebo-controlled crossover trial of famotidine in patients with functional dyspepsia. Aliment Pharmacol Ther 2005; 21 Suppl 2:27-31.
67. Wong WM, Wong BC, Hung WK, Yee YK, Yip AWC, Szeto ML, Fung FMY, Tong TSM, Lai KC, Hu WHC, Yuen MF, Lam SK. Double blind, randomised, placebo controlled study of four weeks of lansoprazole for the treatment of functional dyspepsia in Chinese patients. Gut 2002; 51:502-506.